Antibodies Targeting an Alzheimer’s Gene Effectively Treat Cognitive Impairments in Mice

Antibodies Targeting an Alzheimer’s Gene Effectively Treat Cognitive Impairments in Mice
A new immunotherapy targeting apolipoprotein E4 (apoE4), a genetic variant of apolipoprotein E that increases the risk of early onset Alzheimer's disease (AD), may be a potential therapeutic approach for a good number of patients with the disease, according to researchers at Tel Aviv University, Israel. Researchers, working with mouse models, found that blocking apoE4 in the brain reversed apoE4-induced cognitive impairments in the mice. Their study, "An Anti-apoE4 Specific Monoclonal Antibody Counteracts the Pathological Effects of apoE4 In Vivo," was published in
Subscribe or to access all post and page content.